Acyclovir treatment of varicella in otherwise healthy children1
References (14)
- et al.
Acyclovir therapy of chickenpox in immunosuppressed children: a collaborative study
J Pediatr
(1982) - et al.
A randomized controlled study of intravenous acyclovir (Zovirax) against placebo in adults with chickenpox
J Infect
(1983) - et al.
Laboratory studies of acute varicella and varicella immune status
Diagn Microbiol Infect Dis
(1988) Varicella: complications and costs
Pediatrics
(1986)- et al.
Live attenuated varicella virus vaccine: efficacy trial in healthy children
N Engl J Med
(1984) - et al.
Acyclovir prevents dissemination of varicella in immunocompromised children
J Infect Dis
(1988) - et al.
Therapy of herpes zoster with oral acyclovir
Am J Med
(1988)
Cited by (167)
Varicella and herpes zoster in children
2020, Journal de Pediatrie et de PuericultureVaricella Vaccines
2017, Plotkin's VaccinesPolish consensus guidelines on the use of acyclovir in the treatment and prevention of VZV and HSV infections
2016, Journal of Infection and ChemotherapyCitation Excerpt :A double-blind study assessing the administration of acyclovir (80 mg/kg/day) for 5 days in 815 otherwise healthy children aged 2–12 years old, beginning within 24 h of the onset of a rash, showed a significant reduction in the number of lesions (by approx. 25%) and a one day reduction in the number of days with a fever. The treatment had no effect on the number of complications [1,2]. However, in adolescents and adults the treatment reduced the number of residual hypopigmented lesions on the skin [3].
Vaccination against varicella as post-exposure prophylaxis in adults: A quantitative assessment
2015, VaccineCitation Excerpt :Assuming this proportion was 9.16% as reported in Hanslik et al. [15], number of avoided cases and hospitalizations were more than two times higher: 29 cases and 0.5 hospitalizations avoided per 100,000 adults per year; (3) the efficacy of post-exposure vaccination may be as high as 100% if done early after exposure [12–14,19,27]. As we used 75% efficacy, up to 25% more cases could be avoided; (4) we considered that severity would be independent of the nature of exposure, although intensity of symptoms and number of lesions are higher in familial exposure cases [28–30]. If all severe cases arose from familial exposure, up to 67% hospitalizations could be avoided; (5) we limited assessment to directly avoided cases, and did not take into account cases avoided in pregnant women which may lead to severe sequelae in fetus.
Nosocomial Herpesvirus Infections
2014, Mandell, Douglas, and Bennett's Principles and Practice of Infectious DiseasesChickenpox and Herpes Zoster (Varicella-Zoster Virus)
2014, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
- 1
Supported by grants from the Burroughs Wellcome Company and the Minnesota Medical Foundation.
- *
Now at Baylor College of Medicine, Houston, Texas.